Teachers Retirement System of The State of Kentucky cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 8.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 154,582 shares of the company's stock after selling 15,000 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in AstraZeneca were worth $11,362,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of AZN. Capital International Investors lifted its stake in AstraZeneca by 1.9% in the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock valued at $2,457,706,000 after buying an additional 686,008 shares in the last quarter. Bank of America Corp DE lifted its stake in AstraZeneca by 189.3% in the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after buying an additional 15,722,197 shares in the last quarter. Franklin Resources Inc. lifted its stake in AstraZeneca by 1.9% in the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock valued at $1,276,367,000 after buying an additional 357,894 shares in the last quarter. Sanders Capital LLC lifted its stake in AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock valued at $995,032,000 after buying an additional 212,301 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in AstraZeneca by 13.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,322,388 shares of the company's stock valued at $348,730,000 after buying an additional 636,537 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Stock Down 0.7%
NASDAQ:AZN opened at $68.79 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The stock's fifty day moving average is $70.78 and its two-hundred day moving average is $70.99. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The stock has a market capitalization of $213.34 billion, a price-to-earnings ratio of 27.63, a price-to-earnings-growth ratio of 1.26 and a beta of 0.37.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm's revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.06 earnings per share. Research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts recently weighed in on AZN shares. BNP Paribas started coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.00.
Get Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
